Conditioning regimens for allogeneic stem cell transplants
- 1 November 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 7 (6) , 339-342
- https://doi.org/10.1097/00062752-200011000-00003
Abstract
In addition to providing cytoreduction at myeloablative dose intensity, conditioning regimens for allogeneic transplantation are designed to immunosuppress the recipient to permit donor lymphohematopoietic engraftment and thereby establish a graft-versus-malignancy effect. Increased confidence in the potency of this allogeneic graft-versus-malignancy effect, together with the need to reduce dose intensity to make transplantation safer and more widely applicable in older patients, has led to a conceptual revolution in conditioning regimen design. Novel nonmyeloablative transplant conditioning treatments have low regimen-related toxicity and low transplant-related mortality. The transplants confer a graft-versus-malignancy effect in myeloid and lymphoid malignancies and in metastatic renal cell cancer. Future prospects are for low toxicity conditioning regimens combined with specific antileukemia or antitumor intensification with radioconjugated or unmodified antibodies and the application of highly immunosuppressive but low toxicity conditioning regimens for mismatched transplants.Keywords
This publication has 24 references indexed in Scilit:
- CD34+ cell dose predicts relapse and survival after T‐cell‐depleted HLA‐identical haematopoietic stem cell transplantation (HSCT) for haematological malignanciesBritish Journal of Haematology, 2000
- Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal modelJournal of Clinical Investigation, 2000
- Engraftment Kinetics After Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation: Full Donor T-Cell Chimerism Precedes Alloimmune ResponsesBlood, 1999
- Stable Mixed Hematopoietic Chimerism in Dogs Given Donor Antigen, CTLA4Ig, and 100 cGy Total Body Irradiation Before and Pharmacologic Immunosuppression After Marrow TransplantBlood, 1999
- Stable Mixed Hematopoietic Chimerism in Dog Leukocyte Antigen–Identical Littermate Dogs Given Lymph Node Irradiation Before and Pharmacologic Immunosuppression After Marrow TransplantationBlood, 1999
- Stem cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patientsImmunology Today, 1999
- Mixed lymphohaemopoietic chimerism and graft-ver suslymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantationThe Lancet, 1999
- Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancyCurrent Opinion in Oncology, 1999
- Synergism Between Mycophenolate Mofetil and Cyclosporine in Preventing Graft-Versus-Host Disease Among Lethally Irradiated Dogs Given DLA-Nonidentical Unrelated Marrow GraftsBlood, 1998
- Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic DiseasesBlood, 1998